Rifabutin
- Generic Name
- Rifabutin
- Brand Names
- Mycobutin, Talicia
- Drug Type
- Small Molecule
- Chemical Formula
- C46H62N4O11
- CAS Number
- 72559-06-9
- Unique Ingredient Identifier
- 1W306TDA6S
- Background
A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients.
- Indication
For the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.
- Associated Conditions
- Helicobacter Pylori Infection, Mycobacterium avium complex infection, Tuberculosis (TB), Late phase Tuberculosis
- Associated Therapies
- -
A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia
- Target Recruit Count
- 200
- Registration Number
- NCT00002343
- Locations
- 🇺🇸
Univ of California - Davis Med Ctr / CARES, Sacramento, California, United States
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia
- Target Recruit Count
- 750
- Registration Number
- NCT00002032
- Locations
- 🇺🇸
Mem Hosp Hollywood, Hollywood, Florida, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Univ of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 720
- Registration Number
- NCT00002122
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
🇺🇸UCSD Treatment Ctr / Dept of Medicine and Pediatrics, San Diego, California, United States
🇺🇸Univ of Massachusetts Med Ctr, Worcester, Massachusetts, United States
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pharmacia
- Registration Number
- NCT00002080
- Locations
- 🇺🇸
PACT, Saint Davids, Pennsylvania, United States
The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-10-31
- Target Recruit Count
- 91
- Registration Number
- NCT00001023
- Locations
- 🇺🇸
Univ of Maryland at Baltimore / Veterans Adm, Baltimore, Maryland, United States
🇺🇸Denver Public Health Dept, Denver, Colorado, United States
🇺🇸Med College of Virginia / School of Pharmacy, Richmond, Virginia, United States
Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 31
- Registration Number
- NCT00000877
- Locations
- 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Univ of Southern California / LA County USC Med Cntr, Los Angeles, California, United States
🇺🇸Univ of Miami School of Medicine, Miami, Florida, United States
Effect of Fluconazole, Clarithromycin, and Rifabutin on the Pharmacokinetics of Sulfamethoxazole-Trimethoprim and Dapsone and Their Hydroxylamine Metabolites
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 48
- Registration Number
- NCT00000826
- Locations
- 🇺🇸
University of Washington AIDS CRS, Seattle, Washington, United States
🇺🇸Ucsf Aids Crs, San Francisco, California, United States
Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 400
- Registration Number
- NCT00001047
- Locations
- 🇺🇸
Henry Ford Hosp, Detroit, Michigan, United States
🇺🇸Southern New Jersey AIDS Cln Trials / Dept of Med, Camden, New Jersey, United States
🇺🇸Richmond AIDS Consortium, Richmond, Virginia, United States
The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 1100
- Registration Number
- NCT00001030
- Locations
- 🇺🇸
Cook County Hosp. CORE Ctr., Chicago, Illinois, United States
🇺🇸Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States
🇺🇸Univ. of Miami AIDS CRS, Miami, Florida, United States
Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-09-11
- Target Recruit Count
- 44
- Registration Number
- NCT00004736
- Locations
- 🇺🇸
Univ of California / San Diego Treatment Ctr, San Diego, California, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Vanderbilt Univ Med Ctr, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.